2-(2-aminopyrimidin-4-yl)-1-(2-fluoroethyl)-4-oxo-1,4,6,7-tetrahydropyrrolo[3,2-c]pyridine-5-carboxylic acid tert-butyl ester | 942425-72-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 2-(2-aminopyrimidin-4-yl)-1-(2-fluoroethyl)-4-oxo-1,4,6,7-tetrahydropyrrolo[3,2-c]pyridine-5-carboxylic acid tert-butyl ester
• 英文别名: 2-(2-amino-pyrimidin-4-yl)-1-(2-fluoro-ethyl)-4-oxo-1,4,6,7-tetrahydro-pyrrolo[3,2-c]pyridine-5-carboxylic acid tert-butyl ester；tert-butyl 2-(2-aminopyrimidin-4-yl)-1-(2-fluoroethyl)-4-oxo-6,7-dihydropyrrolo[3,2-c]pyridine-5-carboxylate
• CAS: 942425-72-1
• 化学式: C₁₈H₂₂FN₅O₃
• 分子量: 375.403
• InChiKey: HJPZWCFJTKESRJ-UHFFFAOYSA-N

物化性质

• 沸点：
  611.8±65.0 °C(Predicted)
• 密度：
  1.38±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  103
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-(2-aminopyrimidin-4-yl)-1-(2-fluoroethyl)-4-oxo-1,4,6,7-tetrahydropyrrolo[3,2-c]pyridine-5-carboxylic acid tert-butyl ester 在 碘 、 silver trifluoroacetate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以75%的产率得到2-(2-amino-5-iodo-pyrimidin-4-yl)-1-(2-fluoro-ethyl)-4-oxo-1,4,6,7-tetrahydro-pyrrolo[3,2-c]pyridine-5-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRIMIDINYLPYRROLOPYRIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS
  [FR] DÉRIVÉS DE PYRIMIDINYLPYRROLOPYRIDINONE SUBSTITUÉS, PROCÉDÉ POUR LEUR PRÉPARATION ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE KINASE

  摘要：

  公开了规范中定义的式（I）的嘧啶基吡咯吡啶酮衍生物及其药学上可接受的盐，其制备方法以及包含它们的药物组合物；本发明的化合物可能在治疗中对与蛋白激酶活性失调有关的疾病，如癌症，具有用处。

  公开号：

  WO2010145998A1
• 作为产物：
  描述：

  2-(2-aminopyrimidin-4-yl)-4-oxo-1,4,6,7-tetrahydro-pyrrolo[3,2-c]pyridine-5-carboxylic acid tert-butyl ester 、 1-溴-2-氟乙烷 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 以80%的产率得到2-(2-aminopyrimidin-4-yl)-1-(2-fluoroethyl)-4-oxo-1,4,6,7-tetrahydropyrrolo[3,2-c]pyridine-5-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  N-substituted pyrrolopyridinones active as kinase inhibitors

  摘要：

  由式（I）表示的化合物 其中A，R1，R2，R3，R4，R5和R6如规范中所定义，其药物组成物以及其使用方法。

  公开号：

  US20070142414A1

文献信息

• [EN] SUBSTITUTED PYRROLO-PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRROLOPYRIMIDINE SUBSTITUÉS, LEUR PROCÉDÉ DE PRÉPARATION ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE KINASE
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2009040399A1

  公开（公告）日：2009-04-02

  Substituted pyrrolo-pyrimidine derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a dysregulated protein kinase activity, like cancer.

  公开了公式（I）的取代吡咯-嘧啶衍生物及其药用盐，如规范中定义的，以及它们的制备方法和包含它们的药物组合物；本发明的化合物可能在治疗与蛋白激酶活性失调相关的疾病，如癌症中有用。
• SUBSTITUTED PYRIMIDINYLPYRROLOPYRIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS
  申请人：Marchionni Chiara

  公开号：US20120178770A1

  公开（公告）日：2012-07-12

  Pyrimidinylpyrrolopyridinone derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

  本发明公开了式（I）中定义的嘧啶基吡咯吡啶酮衍生物及其药学上可接受的盐，以及制备它们的方法和包含它们的制药组合物；该发明的化合物可能在治疗与蛋白激酶活性失调有关的疾病，如癌症中有用。
• Substituted Pyrrolo-Pyrimidine Derivatives, Process for Their Preparation and Their Use as Kinase Inhibitors
  申请人：Caruso Michele

  公开号：US20120122882A1

  公开（公告）日：2012-05-17

  Substituted pyrrolo-pyrimidine derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a dysregulated protein kinase activity, like cancer.

  本文披露了公式(I)的取代嘧啶-吡咯衍生物及其药学上可接受的盐，以及其制备方法和包含它们的制药组合物；本发明的化合物可能在治疗与蛋白激酶活性失调相关的疾病，如癌症方面具有用途。
• Cdc7 Kinase Inhibitors: Pyrrolopyridinones as Potential Antitumor Agents. 1. Synthesis and Structure–Activity Relationships
  作者：Ermes Vanotti、Raffaella Amici、Alberto Bargiotti、Jens Berthelsen、Roberta Bosotti、Antonella Ciavolella、Alessandra Cirla、Cinzia Cristiani、Roberto D’Alessio、Barbara Forte、Antonella Isacchi、Katia Martina、Maria Menichincheri、Antonio Molinari、Alessia Montagnoli、Paolo Orsini、Antonio Pillan、Fulvia Roletto、Alessandra Scolaro、Marcellino Tibolla、Barbara Valsasina、Mario Varasi、Daniele Volpi、Corrado Santocanale

  DOI：10.1021/jm700956r

  日期：2008.2.1

  Cdc7 kinase is an essential protein that promotes DNA replication in eukaryotic organisms. Genetic evidence indicates that Cdc7 inhibition can cause selective tumor-cell death in a p53-independent manner, supporting the rationale for developing Cdc7 small-molecule inhibitors for the treatment of cancers. In this paper, the synthesis and structure-activity relationships of 2-heteroaryl-pyrrolopyridinones, the first potent Cdc7 kinase inhibitors, are,described. Starting from 2-pyridin-4-yl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one, progress toward a simple scaffold, tailored for Cdc7 inhibition, is reported.
• SUBSTITUTED PYRROLO-PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS
  申请人：Nerviano Medical Sciences S.r.l.

  公开号：EP2203442B1

  公开（公告）日：2012-06-20